Last10K.com

Anixa Biosciences Inc (ANIX) SEC Filing 10-Q Quarterly report for the period ending Thursday, April 30, 2020

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX
Document And Entity Information - shares
6 Months Ended
Apr. 30, 2020
Jun. 09, 2020
Document Information Line Items  
Entity Registrant NameAnixa Biosciences Inc 
Document Type10-Q 
Current Fiscal Year End Date--10-31 
Entity Common Stock, Shares Outstanding 22,975,950
Amendment Flagfalse 
Entity Central Index Key0000715446 
Entity Current Reporting StatusYes 
Entity Filer CategoryNon-accelerated Filer 
Document Period End DateApr. 30, 2020 
Document Fiscal Year Focus2020 
Document Fiscal Period FocusQ2 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Interactive Data CurrentYes 

View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
Other
Filter by Subcategory:
All
Expense
Product
Earnings
Cash Flow
Income
Other
Inside Anixa Biosciences Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parentheticals)
Condensed Consolidated Statement Of Shareholders' Equity (Unaudited)
Condensed Consolidated Statement Of Shareholders' Equity (Unaudited) (Parentheticals)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited) (Parentheticals)
Accrued Expenses
Accrued Expenses (Details) - Accrued Expenses
Accrued Expenses (Tables)
Business And Funding
Business And Funding (Details)
Business And Funding (Details) - Changes In Noncontrolling Interest
Business And Funding (Tables)
Commitment And Contingences
Effect Of Recently Adopted And Issued Pronouncements
Fair Value Measurements
Fair Value Measurements (Details) - Hierarchy For Financial Assets Measured At Fair Value
Fair Value Measurements (Details) - Hierarchy For Financial Liabilities Measured At Fair Value
Fair Value Measurements (Tables)
Impact Of Coronavirus Pandemic
Income Taxes
Leases
Leases (Details)
Leases (Details) - Annual Minimum Lease Payments
Leases (Details) - Balance Sheet Information Related To The Company`S Lease
Leases (Tables)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Details)
Segment Information
Segment Information (Details)
Segment Information (Details) - Segments Information
Segment Information (Tables)
Stock Based Compensation
Stock Based Compensation (Details) - Employee Stock Purchase Plan
Stock Based Compensation (Details) - Information Regarding The Stock Option Plan
Stock Based Compensation (Details) - Stock Awards
Stock Based Compensation (Details) - Stock Option Activity
Stock Based Compensation (Details) - Stock Option Compensation Expense
Stock Based Compensation (Details) - Stock Option Plans
Stock Based Compensation (Details) - Stock Options Outstanding And Exercisable Under The Stock Option Plan
Stock Based Compensation (Details) - Warrants
Stock Based Compensation (Tables)
Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001513162-20-000122
Submitted to the SEC: Tue Jun 09 2020 5:11:27 PM EST
Accepted by the SEC: Tue Jun 09 2020
Period: Thursday, April 30, 2020
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001513162-20-000122.htm